KR20220110731A - 치매에서의 glp-1 수용체 작용제 - Google Patents

치매에서의 glp-1 수용체 작용제 Download PDF

Info

Publication number
KR20220110731A
KR20220110731A KR1020227015440A KR20227015440A KR20220110731A KR 20220110731 A KR20220110731 A KR 20220110731A KR 1020227015440 A KR1020227015440 A KR 1020227015440A KR 20227015440 A KR20227015440 A KR 20227015440A KR 20220110731 A KR20220110731 A KR 20220110731A
Authority
KR
South Korea
Prior art keywords
glp
dementia
receptor agonist
disease
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227015440A
Other languages
English (en)
Korean (ko)
Inventor
사라 프리에드리치
샤롯데 크리스틴 팀 한센
로테 브제르 누드센
안나 세체르
Original Assignee
노보 노르디스크 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=73172681&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20220110731(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노보 노르디스크 에이/에스 filed Critical 노보 노르디스크 에이/에스
Publication of KR20220110731A publication Critical patent/KR20220110731A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227015440A 2019-11-06 2020-11-05 치매에서의 glp-1 수용체 작용제 Pending KR20220110731A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19207501.8 2019-11-06
EP19207501 2019-11-06
EP20186623 2020-07-20
EP20186623.3 2020-07-20
PCT/EP2020/081087 WO2021089678A1 (en) 2019-11-06 2020-11-05 Glp-1 receptor agonists in dementia

Publications (1)

Publication Number Publication Date
KR20220110731A true KR20220110731A (ko) 2022-08-09

Family

ID=73172681

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227015440A Pending KR20220110731A (ko) 2019-11-06 2020-11-05 치매에서의 glp-1 수용체 작용제

Country Status (19)

Country Link
US (4) US20220280612A1 (cg-RX-API-DMAC7.html)
EP (2) EP4054620B1 (cg-RX-API-DMAC7.html)
JP (2) JP7670698B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220110731A (cg-RX-API-DMAC7.html)
CN (1) CN114728042A (cg-RX-API-DMAC7.html)
AU (1) AU2020377469A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022007721A2 (cg-RX-API-DMAC7.html)
CA (1) CA3154744A1 (cg-RX-API-DMAC7.html)
ES (1) ES2984177T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241052T1 (cg-RX-API-DMAC7.html)
HU (1) HUE067514T2 (cg-RX-API-DMAC7.html)
IL (1) IL291876A (cg-RX-API-DMAC7.html)
MA (1) MA57599B1 (cg-RX-API-DMAC7.html)
MX (1) MX2022004779A (cg-RX-API-DMAC7.html)
PH (1) PH12022550842A1 (cg-RX-API-DMAC7.html)
PL (1) PL4054620T3 (cg-RX-API-DMAC7.html)
RS (1) RS65780B1 (cg-RX-API-DMAC7.html)
TW (2) TWI890704B (cg-RX-API-DMAC7.html)
WO (1) WO2021089678A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3154744A1 (en) 2019-11-06 2021-05-14 Sarah FRIEDRICH Glp-1 receptor agonists in dementia
US20230088005A1 (en) * 2020-01-30 2023-03-23 Eli Lilly And Company Therapeutic uses of dulaglutide
EP4262873A4 (en) * 2020-12-16 2024-12-11 The Chinese University of Hong Kong A method for reversing aging brain functional decline
CN118510545A (zh) 2021-12-02 2024-08-16 哥本哈根大学 用于治疗神经退行性疾病的肽-药物缀合物
CN120731085A (zh) * 2023-03-02 2025-09-30 甘李药业股份有限公司 一种glp-1化合物的医药用途
WO2026096637A1 (en) * 2024-10-30 2026-05-07 Tiziana Life Sciences Plc Glp-1 agonists and foralumab combination therapies
CN120131965A (zh) * 2025-04-10 2025-06-13 瓯江实验室 Glp-1受体激动剂治疗阿尔茨海默病的用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
AU3357800A (en) 1999-02-05 2000-08-25 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
AU2001275231A1 (en) 2000-06-02 2001-12-11 Emisphere Technologies, Inc. Method of preparing salicylamides
EP1411968B1 (en) 2001-07-31 2008-09-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Glp-1 exendin-4 peptide analogs and uses thereof
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
MX2008001468A (es) 2005-06-30 2008-04-07 Sod Conseils Rech Applic Composiciones farmaceuticas del peptido similar al glucagon-1.
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
EP2066337A2 (en) 2006-08-04 2009-06-10 Amylin Pharmaceuticals, Inc. Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen
MX2009002121A (es) 2006-09-07 2009-05-20 Hoffmann La Roche Proceso para la manufactura del acido n-(8-[2-hidroxibenzoil]-amin o)caprilico.
US8756102B2 (en) * 2009-11-06 2014-06-17 Edatanetworks Inc. Method, system, and computer program for attracting local and regional businesses to an automated cause marketing environment
US20120329711A1 (en) 2009-12-16 2012-12-27 Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
AU2012241894B2 (en) 2011-04-12 2015-12-03 Novo Nordisk A/S Double-acylated GLP-1 derivatives
WO2013004983A1 (en) 2011-07-04 2013-01-10 Imperial Innovations Limited Novel compounds and their effects on feeding behaviour
HUE049152T2 (hu) * 2012-07-01 2020-09-28 Novo Nordisk As Hosszantartó hatású GLP-1 peptidek alkalmazása
WO2015155151A1 (en) 2014-04-07 2015-10-15 Novo Nordisk A/S Double-acylated glp-1 compounds
WO2016198624A1 (en) * 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
US20170112897A1 (en) * 2015-10-23 2017-04-27 Cedars-Sinai Medical Center Methods for treating brain insulin resistance
AU2016379403B2 (en) * 2015-12-23 2020-03-12 The Johns Hopkins University Long-acting GLP-1r agonist as a therapy of neurological and neurodegenerative conditions
US20190142905A1 (en) 2016-04-19 2019-05-16 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use
GB201620611D0 (en) 2016-12-05 2017-01-18 Univ Of Lancaster Treatment of neurological diseases
CA3154744A1 (en) 2019-11-06 2021-05-14 Sarah FRIEDRICH Glp-1 receptor agonists in dementia
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses

Also Published As

Publication number Publication date
RS65780B1 (sr) 2024-08-30
WO2021089678A1 (en) 2021-05-14
EP4054620A1 (en) 2022-09-14
EP4414031A3 (en) 2025-02-05
TW202519256A (zh) 2025-05-16
ES2984177T3 (es) 2024-10-29
MA57599B1 (fr) 2024-06-28
MX2022004779A (es) 2022-06-14
TWI923289B (zh) 2026-04-21
JP2023500032A (ja) 2023-01-04
IL291876A (en) 2022-06-01
EP4054620C0 (en) 2024-05-29
BR112022007721A2 (pt) 2022-07-12
PL4054620T3 (pl) 2024-10-14
CA3154744A1 (en) 2021-05-14
EP4414031A2 (en) 2024-08-14
TW202118509A (zh) 2021-05-16
US20220280612A1 (en) 2022-09-08
EP4054620B1 (en) 2024-05-29
US12539326B2 (en) 2026-02-03
US20240207364A1 (en) 2024-06-27
TWI890704B (zh) 2025-07-21
HRP20241052T1 (hr) 2024-11-08
US20250099549A1 (en) 2025-03-27
JP7670698B2 (ja) 2025-04-30
PH12022550842A1 (en) 2023-10-09
CN114728042A (zh) 2022-07-08
US20230302094A1 (en) 2023-09-28
AU2020377469A1 (en) 2022-04-28
HUE067514T2 (hu) 2024-10-28
JP2025027130A (ja) 2025-02-26

Similar Documents

Publication Publication Date Title
JP7670698B2 (ja) 認知症におけるglp-1受容体作動薬
Watson et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study
JP6941109B2 (ja) Fxrアゴニストを使用するための方法
ES2487897T3 (es) Combinaciones que consisten de inhibidores de la dipeptidilpeptidasa-IV y agentes antidiabéticos
Cohen et al. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study
KR101937782B1 (ko) 바클로펜 및 아캄프로세이트에 기초한 신경 장애의 치료
TWI791507B (zh) 使用ccr3-抑制劑治療老化相關損傷之方法及組合物
CN113950328A (zh) 用于治疗亨廷顿病及其症状的包含普利多匹定及其类似物的组合物
CA3174964A1 (en) Semaglutide for the treatment of non-alcoholic steatohepatitis
CN117355297A (zh) 用于诱导褐色脂肪生成的方法和组合物
US10172920B2 (en) Sleep apnea treatment
JP2024153742A (ja) Ccr3阻害剤を用いて、加齢性機能障害を治療するための方法および組成物
EA052078B1 (ru) Агонисты рецептора glp-1 при лечении деменции
EA046973B1 (ru) Агонисты рецептора glp-1 при лечении деменции
HK40075453A (en) Semaglutide in the treatment of alzheimer's dementia
US20180326014A1 (en) Pharmaceutical formulations for the treatment of diabetes
WO2026093539A1 (en) Methods of treating or managing obesity
HK40053020A (en) Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
EA048593B1 (ru) Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов
HK1155659B (en) Pharmaceutical composition for treatment of fibromyalgia
HK1155659A1 (en) Pharmaceutical composition for treatment of fibromyalgia

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20220506

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20231023

Comment text: Request for Examination of Application